Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer

BACKGROUND: A nivolumab monotherapy flat-dosing regimen of 480 mg every 4 weeks (Q4W) has been approved in several markets, including the United States, Canada, and European Union, as an alternative dosing regimen for several indications. Approvals of this Q4W regimen were based on population pharma...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Ann Oncol
Prif Awduron: Long, G V, Tykodi, S S, Schneider, J G, Garbe, C, Gravis, G, Rashford, M, Agrawal, S, Grigoryeva, E, Bello, A, Roy, A, Rollin, L, Zhao, X
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Oxford University Press 2018
Pynciau:
Original Articles
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6290887/
https://ncbi.nlm.nih.gov/pubmed/30215677
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdy408
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg